Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas
✍ Scribed by Michael Glantz; Marc Chamberlain; Qin Liu; N. Scott Litofsky; Lawrence D. Recht
- Publisher
- John Wiley and Sons
- Year
- 2003
- Tongue
- English
- Weight
- 78 KB
- Volume
- 97
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
BACKGROUND
The optimal treatment for elderly patients (defined as patients 70 years of age or older) with malignant gliomas (MG) remains controversial. Some physicians advocate withholding therapy following diagnosis based on the observation that elderly patients do not tolerate adjuvant radiotherapy. The availability of temozolomide (TMZ), a new alkylating agent with antiglioma efficacy, offers another potential therapeutic option for these patients. The drug can be administered orally at home with minimal morbidity.
METHODS
The authors retrospectively reviewed a cohort of 86 consecutive elderly MG patients from three institutions, 32 of whom received monthly TMZ in lieu of radiation.
RESULTS
Initial Karnofsky performance score was the only predictor of survival in this cohort. No difference in survival was noted between these two groups. Toxicity was minimal in the chemotherapy‐treated group and a higher percentage of patients receiving chemotherapy died at home.
CONCLUSIONS
The authors concluded that TMZ is as effective as irradiation as a treatment of elderly patients with MG. It is an alternative and, perhaps, a superior therapeutic option to irradiation, based on its ease of administration and low morbidity. Cancer 2003;97:2262–6. © 2003 American Cancer Society.
DOI 10.1002/cncr.11323